9706291-4
IPDS
copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 9/22 — A1

(11) International Publication Number: WO 96/39127

(43) International Publication Date: 12 December 1996 (12.12.96)

(21) International Application Number: PCT/US96/09016

(22) International Filing Date: 6 June 1996 (06.06.96)

(30) Priority Data:
08/472,693 — 6 June 1995 (06.06.95) — US

(60) Parent Application or Grant
(63) Related by Continuation
US — 08/472,693 (CON)
Filed on — 6 June 1995 (06.06.95)

(71) Applicant *(for all designated States except US)*: CHURCH & DWIGHT CO., INC. [US/US]; 469 North Harrison Street, Princeton, NJ 08540 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: MARDER, Herman [US/US]; 29 Constitution Hill West, Princeton, NJ 08540 (US). KIRSCHNER, Lawrence [US/US]; 33 Deer Path Drive, Flanders, NJ 07836 (US). STEINKE, John, J. [US/US]; 389 East State Street, Doylestown, PA 18901 (US). KURTZ, Andrew, D. [US/US]; 12 Heather Lane, Belle Mead, NJ 08502 (US). BERTELSEN, Poul [DK/DK]; Duery 42, DK-2000 Frederiksberg (DK). HANSEN, Nils, Gjerlov [DK/DK]; Kristian Zaartmanns Plans 76, DK-2000 Frederiksberg (DK). HJORTH, Thyge, Borup [DK/DK]; Solbakken 5, DK-3520 Farum (DK).

(74) Agent: GROSS, Marc, S.; Bryan Cave L.L.P., 40th floor, 245 Park Avenue, New York, NY 10167 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: ALKALINIZING POTASSIUM SALT CONTROLLED RELEASE PREPARATIONS

(57) Abstract

Multiparticulate controlled release preparations incorporating an alkalinizing potassium salt, preferably potassium bicarbonate, as an active ingredient, which are suitable for forming pharmaceutical dosage forms for oral administration. Such dosage forms are useful for potassium supplementation and for the treatement of degenerative bone or cardiovascular diseases, e.g., osteoporosis and hypertension.